期刊文献+

肠源性内毒素血症:非酒精性脂肪性肝炎的重要危险因素 被引量:8

Intestinal Endotoxemia:An Important Risk Factor of Non-alcoholic Steatohepatitis
下载PDF
导出
摘要 非酒精性脂肪性肝病(NAFLD)是指除外酒精和其他明确损肝因素所致的、以肝细胞脂肪变性和脂质沉积为主要特征的临床病理综合征。非酒精性脂肪性肝炎(NASH)是NAFLD病程进展中的主要阶段。近年多项研究发现肠源性内毒素血症与NASH关系密切,本文就肠源性内毒素血症所致的肥胖和肝脏损伤对NASH发生的影响作一综述。 Non-alcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome characterized by hepatic steatosis and fat deposition in hepatocytes without excessive alcohol intake and other liver injury factors. Non-alcoholic steatohepatitis (NASH) is a main phase of progression in NAFLD. Recently, studies have shown that intestinal endotoxemia is closely related to NASH. This article reviewed the effect of obesity and liver injury induced by intestinal endotoxemia on the development of NASH.
出处 《胃肠病学》 2010年第9期562-564,共3页 Chinese Journal of Gastroenterology
关键词 内毒素血症 非酒精性脂肪性肝炎 肥胖症 脂多糖类 枯否细胞 危险因素 Endotoxemia Non-Alcoholic Steatohepatitis Obesity Lipopolysaceharides Kupffer Cells Risk Factors
  • 相关文献

参考文献4

二级参考文献18

共引文献212

同被引文献82

  • 1中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华糖尿病杂志,2010,2(1). 被引量:527
  • 2王晓晟,张淑慧.双歧三联活菌对老年肺炎后全身炎症反应综合征患者的肠道屏障保护作用[J].中国微生态学杂志,2005,17(6):444-445. 被引量:6
  • 3韩德五.肠源性内毒素血症是肝炎、肝病的危险因素[J].山西医科大学学报,2006,37(1):1-4. 被引量:39
  • 4于洪波,戴林,彭海英,左中.微生态制剂防治大鼠非酒精性脂肪肝炎模型作用机制的实验研究[J].临床消化病杂志,2006,18(6):350-352. 被引量:11
  • 5Wellen KE, Hotamisligil GS. Inflammation, stress, and di- abetes[J]. J Clin Invest, 2005, 115(5): 1111-1119.
  • 6Cani PD, Delzenne NM. Involvement of the gut microbiota in the development of low grade inflammation associated with obesity: focus on this neglected partner [J]. Acta Gastroenterol Belg, 2010, 73(2): 267-269.
  • 7Cani PD, Amar J, Iglesias MA, et al. Metabolic endotox- emia initiates obesity and insulin resistance [J]. Diabetes, 2007, 56(7): 1761-1772.
  • 8Giannini S, Serio M, Galli A. Pleiotropic effects of thiazo- lidinediones: taking a look beyond antidiabetic activity[J]. J Endocrinol Invest, 2004, 27(10): 982-991.
  • 9Karagiannis E, Pfiitzner A, Forst T, et al. The IRIS V study: pioglitazone improves systemic chronic inflamma- tion in patients with type 2 diabetes under daily routine conditions[J]. Diabetes Technol Ther, 2008, 10(3): 206-212.
  • 10Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Associa- tion[J]. Circulation, 2003, 107(3): 499-511.

引证文献8

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部